How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
45
ENZN Quote, Financials, Valuation and Earnings
Last price:
$0.07
Seasonality move
:
-3.97%
Day range:
$0.06 - $0.07
52-week range:
$0.03 - $0.18
Dividend yield:
0%
P/E ratio:
96.91x
P/S ratio:
225.50x
P/B ratio:
9.54x
Volume:
19.3K
Avg. volume:
91.7K
1-year change:
-59.72%
Market cap:
$5M
Revenue:
$26K
EPS (TTM):
-$0.05
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ENZN
Enzon Pharmaceuticals, Inc.
|
-- | -- | -- | -- | -- |
|
AGEN
Agenus, Inc.
|
$28.1M | -$1.30 | 329.24% | -36.28% | $12.33 |
|
CRIS
Curis, Inc.
|
$3.2M | -$0.43 | -2.86% | -65.51% | $14.00 |
|
LADX
LadRx Corp.
|
-- | -- | -- | -- | -- |
|
PSTV
Plus Therapeutics, Inc.
|
$1.2M | -$0.04 | 22.78% | -97.49% | $5.50 |
|
WINT
Windtree Therapeutics, Inc.
|
-- | -$39.00 | -- | -94.17% | $4.0000 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ENZN
Enzon Pharmaceuticals, Inc.
|
$0.07 | -- | $5M | 96.91x | $0.00 | 0% | 225.50x |
|
AGEN
Agenus, Inc.
|
$2.94 | $12.33 | $100M | -- | $0.00 | 0% | 0.74x |
|
CRIS
Curis, Inc.
|
$1.03 | $14.00 | $13.3M | -- | $0.00 | 0% | 0.98x |
|
LADX
LadRx Corp.
|
$0.10 | -- | $51.2K | 0.84x | $0.00 | 0% | -- |
|
PSTV
Plus Therapeutics, Inc.
|
$0.26 | $5.50 | $35.7M | -- | $0.00 | 0% | 4.17x |
|
WINT
Windtree Therapeutics, Inc.
|
$0.0100 | $4.0000 | $337.1K | 0.00x | $0.00 | 0% | 0.26x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ENZN
Enzon Pharmaceuticals, Inc.
|
-- | 2.463 | -- | 80.10x |
|
AGEN
Agenus, Inc.
|
510.35% | 4.019 | 285.06% | 0.03x |
|
CRIS
Curis, Inc.
|
192.35% | 2.868 | 144.76% | 0.62x |
|
LADX
LadRx Corp.
|
-- | 2.863 | -- | -- |
|
PSTV
Plus Therapeutics, Inc.
|
0.41% | -1.387 | 0.02% | 1.22x |
|
WINT
Windtree Therapeutics, Inc.
|
974.23% | 2.926 | 568.87% | 0.01x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ENZN
Enzon Pharmaceuticals, Inc.
|
-- | -$229K | -5.37% | -5.37% | -1250% | -$1M |
|
AGEN
Agenus, Inc.
|
$26.6M | -$4.9M | -39.69% | -- | -16.08% | -$14.7M |
|
CRIS
Curis, Inc.
|
$3.1M | -$6.9M | -147.67% | -461.34% | -218.01% | -$5.6M |
|
LADX
LadRx Corp.
|
-- | -$719.8K | -- | -- | -- | -$552.8K |
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$4.5M | -- | -- | -320.83% | -$2.6M |
|
WINT
Windtree Therapeutics, Inc.
|
-$360K | -$3.8M | -320.18% | -760.4% | -- | -$6.4M |
Enzon Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns ENZN or AGEN?
Agenus, Inc. has a net margin of -- compared to Enzon Pharmaceuticals, Inc.'s net margin of -116.82%. Enzon Pharmaceuticals, Inc.'s return on equity of -5.37% beat Agenus, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ENZNEnzon Pharmaceuticals, Inc.-- -$0.02 $43.2M AGENAgenus, Inc.87.85% $1.94 $60.1M -
What do Analysts Say About ENZN or AGEN?
Enzon Pharmaceuticals, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 319.5%. Given that Agenus, Inc. has higher upside potential than Enzon Pharmaceuticals, Inc., analysts believe Agenus, Inc. is more attractive than Enzon Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ENZNEnzon Pharmaceuticals, Inc.0 0 0 AGENAgenus, Inc.2 1 0 -
Is ENZN or AGEN More Risky?
Enzon Pharmaceuticals, Inc. has a beta of 0.196, which suggesting that the stock is 80.447% less volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.619, suggesting its more volatile than the S&P 500 by 61.86%.
-
Which is a Better Dividend Stock ENZN or AGEN?
Enzon Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enzon Pharmaceuticals, Inc. pays -163.88% of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENZN or AGEN?
Enzon Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Agenus, Inc. quarterly revenues of $30.2M. Enzon Pharmaceuticals, Inc.'s net income of -$824K is lower than Agenus, Inc.'s net income of $63.9M. Notably, Enzon Pharmaceuticals, Inc.'s price-to-earnings ratio is 96.91x while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enzon Pharmaceuticals, Inc. is 225.50x versus 0.74x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENZNEnzon Pharmaceuticals, Inc.225.50x 96.91x -- -$824K AGENAgenus, Inc.0.74x -- $30.2M $63.9M
-
Which has Higher Returns ENZN or CRIS?
Curis, Inc. has a net margin of -- compared to Enzon Pharmaceuticals, Inc.'s net margin of -243.36%. Enzon Pharmaceuticals, Inc.'s return on equity of -5.37% beat Curis, Inc.'s return on equity of -461.34%.
Company Gross Margin Earnings Per Share Invested Capital ENZNEnzon Pharmaceuticals, Inc.-- -$0.02 $43.2M CRISCuris, Inc.98.52% -$0.49 $15.9M -
What do Analysts Say About ENZN or CRIS?
Enzon Pharmaceuticals, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Curis, Inc. has an analysts' consensus of $14.00 which suggests that it could grow by 1259.22%. Given that Curis, Inc. has higher upside potential than Enzon Pharmaceuticals, Inc., analysts believe Curis, Inc. is more attractive than Enzon Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ENZNEnzon Pharmaceuticals, Inc.0 0 0 CRISCuris, Inc.4 0 0 -
Is ENZN or CRIS More Risky?
Enzon Pharmaceuticals, Inc. has a beta of 0.196, which suggesting that the stock is 80.447% less volatile than S&P 500. In comparison Curis, Inc. has a beta of 3.078, suggesting its more volatile than the S&P 500 by 207.818%.
-
Which is a Better Dividend Stock ENZN or CRIS?
Enzon Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Curis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enzon Pharmaceuticals, Inc. pays -163.88% of its earnings as a dividend. Curis, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENZN or CRIS?
Enzon Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Curis, Inc. quarterly revenues of $3.2M. Enzon Pharmaceuticals, Inc.'s net income of -$824K is higher than Curis, Inc.'s net income of -$7.7M. Notably, Enzon Pharmaceuticals, Inc.'s price-to-earnings ratio is 96.91x while Curis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enzon Pharmaceuticals, Inc. is 225.50x versus 0.98x for Curis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENZNEnzon Pharmaceuticals, Inc.225.50x 96.91x -- -$824K CRISCuris, Inc.0.98x -- $3.2M -$7.7M
-
Which has Higher Returns ENZN or LADX?
LadRx Corp. has a net margin of -- compared to Enzon Pharmaceuticals, Inc.'s net margin of --. Enzon Pharmaceuticals, Inc.'s return on equity of -5.37% beat LadRx Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ENZNEnzon Pharmaceuticals, Inc.-- -$0.02 $43.2M LADXLadRx Corp.-- -$1.45 -- -
What do Analysts Say About ENZN or LADX?
Enzon Pharmaceuticals, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand LadRx Corp. has an analysts' consensus of -- which suggests that it could grow by 434682.61%. Given that LadRx Corp. has higher upside potential than Enzon Pharmaceuticals, Inc., analysts believe LadRx Corp. is more attractive than Enzon Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ENZNEnzon Pharmaceuticals, Inc.0 0 0 LADXLadRx Corp.0 0 0 -
Is ENZN or LADX More Risky?
Enzon Pharmaceuticals, Inc. has a beta of 0.196, which suggesting that the stock is 80.447% less volatile than S&P 500. In comparison LadRx Corp. has a beta of 0.464, suggesting its less volatile than the S&P 500 by 53.583%.
-
Which is a Better Dividend Stock ENZN or LADX?
Enzon Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LadRx Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enzon Pharmaceuticals, Inc. pays -163.88% of its earnings as a dividend. LadRx Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENZN or LADX?
Enzon Pharmaceuticals, Inc. quarterly revenues are --, which are larger than LadRx Corp. quarterly revenues of --. Enzon Pharmaceuticals, Inc.'s net income of -$824K is lower than LadRx Corp.'s net income of -$719.3K. Notably, Enzon Pharmaceuticals, Inc.'s price-to-earnings ratio is 96.91x while LadRx Corp.'s PE ratio is 0.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enzon Pharmaceuticals, Inc. is 225.50x versus -- for LadRx Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENZNEnzon Pharmaceuticals, Inc.225.50x 96.91x -- -$824K LADXLadRx Corp.-- 0.84x -- -$719.3K
-
Which has Higher Returns ENZN or PSTV?
Plus Therapeutics, Inc. has a net margin of -- compared to Enzon Pharmaceuticals, Inc.'s net margin of -316.61%. Enzon Pharmaceuticals, Inc.'s return on equity of -5.37% beat Plus Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ENZNEnzon Pharmaceuticals, Inc.-- -$0.02 $43.2M PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M -
What do Analysts Say About ENZN or PSTV?
Enzon Pharmaceuticals, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 2016.2%. Given that Plus Therapeutics, Inc. has higher upside potential than Enzon Pharmaceuticals, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Enzon Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ENZNEnzon Pharmaceuticals, Inc.0 0 0 PSTVPlus Therapeutics, Inc.4 0 0 -
Is ENZN or PSTV More Risky?
Enzon Pharmaceuticals, Inc. has a beta of 0.196, which suggesting that the stock is 80.447% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.
-
Which is a Better Dividend Stock ENZN or PSTV?
Enzon Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enzon Pharmaceuticals, Inc. pays -163.88% of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENZN or PSTV?
Enzon Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Enzon Pharmaceuticals, Inc.'s net income of -$824K is higher than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Enzon Pharmaceuticals, Inc.'s price-to-earnings ratio is 96.91x while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enzon Pharmaceuticals, Inc. is 225.50x versus 4.17x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENZNEnzon Pharmaceuticals, Inc.225.50x 96.91x -- -$824K PSTVPlus Therapeutics, Inc.4.17x -- $1.4M -$4.4M
-
Which has Higher Returns ENZN or WINT?
Windtree Therapeutics, Inc. has a net margin of -- compared to Enzon Pharmaceuticals, Inc.'s net margin of --. Enzon Pharmaceuticals, Inc.'s return on equity of -5.37% beat Windtree Therapeutics, Inc.'s return on equity of -760.4%.
Company Gross Margin Earnings Per Share Invested Capital ENZNEnzon Pharmaceuticals, Inc.-- -$0.02 $43.2M WINTWindtree Therapeutics, Inc.-- -$1.08 $1.3M -
What do Analysts Say About ENZN or WINT?
Enzon Pharmaceuticals, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Windtree Therapeutics, Inc. has an analysts' consensus of $4.0000 which suggests that it could grow by 39900%. Given that Windtree Therapeutics, Inc. has higher upside potential than Enzon Pharmaceuticals, Inc., analysts believe Windtree Therapeutics, Inc. is more attractive than Enzon Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ENZNEnzon Pharmaceuticals, Inc.0 0 0 WINTWindtree Therapeutics, Inc.0 0 0 -
Is ENZN or WINT More Risky?
Enzon Pharmaceuticals, Inc. has a beta of 0.196, which suggesting that the stock is 80.447% less volatile than S&P 500. In comparison Windtree Therapeutics, Inc. has a beta of 0.663, suggesting its less volatile than the S&P 500 by 33.733%.
-
Which is a Better Dividend Stock ENZN or WINT?
Enzon Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Windtree Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enzon Pharmaceuticals, Inc. pays -163.88% of its earnings as a dividend. Windtree Therapeutics, Inc. pays out 36.77% of its earnings as a dividend. Windtree Therapeutics, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ENZN or WINT?
Enzon Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Windtree Therapeutics, Inc. quarterly revenues of --. Enzon Pharmaceuticals, Inc.'s net income of -$824K is higher than Windtree Therapeutics, Inc.'s net income of -$28.1M. Notably, Enzon Pharmaceuticals, Inc.'s price-to-earnings ratio is 96.91x while Windtree Therapeutics, Inc.'s PE ratio is 0.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enzon Pharmaceuticals, Inc. is 225.50x versus 0.26x for Windtree Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENZNEnzon Pharmaceuticals, Inc.225.50x 96.91x -- -$824K WINTWindtree Therapeutics, Inc.0.26x 0.00x -- -$28.1M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
53
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 30x
Alerts
Sell
40
BILL alert for Feb 7
Bill Holdings, Inc. [BILL] is up 37.11% over the past day.
Buy
75
PRLB alert for Feb 7
Proto Labs, Inc. [PRLB] is up 28.33% over the past day.
Sell
30
MSTR alert for Feb 7
Strategy, Inc. [MSTR] is up 26.08% over the past day.
